DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Fallopian Tube Carcinosarcoma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFallopian Tube Carcinosarcoma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fallopian tube carcinosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p53 (TP53) — TP53 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9R2Q · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Primary fallopian tube carcinoma accounts for about 1% of gynaecologic malignancies. In a series of 37 patients treated between 1946 and 1976, the overall five-year survival rate was 30%, with 42% for early-stage tumours; the extent of disease at diagnosis was the single most important prognostic factor. A 1989 study of 46 patients with measurable advanced or recurrent disease reported response rates of 9% with single-agent chemotherapy, 29% with multiagent therapy without cisplatin, and 81% with cisplatin-containing combination therapy. Survival for stage III/IV patients was significantly improved with the addition of cisplatin-based combination therapy.
Carcinosarcoma of the fallopian tube is extremely rare. A review of 59 cases (including four new ones) found three-year survival rates of 63% for 27 stage I/II patients and 40% for 24 stage III/IV patients. Among treatment groups, three-year survival was 36% for 14 surgery-alone patients, 59% for 13 patients receiving radiation after surgery, 54% for 27 patients receiving chemotherapy after surgery, and 100% for four patients receiving chemoradiotherapy after surgery. The difference between surgery-alone and chemotherapy groups was significant (P < 0.05). When a platinum drug was used, the three-year survival rate for all stages was 63% versus 21% when it was not used. The authors concluded that platinum-based chemotherapy after surgery appears most effective.
A 2021 case report described a 55-year-old woman with carcinosarcoma of the fallopian tube who underwent cytoreductive surgery and postoperative platinum-based combination therapy plus bevacizumab; no evidence of disease was found 51 months after resection. A 2020 case reported a 42-year-old woman with metastatic primary fallopian tube carcinoma who had failed multiple systemic therapies and antiangiogenic therapy over nine years, then received pembrolizumab combined with nab-paclitaxel and showed a complete response after six cycles, remaining in good health on maintenance pembrolizumab. The authors noted that more clinical evidence is needed to confirm efficacy and safety.
What remains missing are prospective trials large enough to establish a standard therapy for this rare disease, adequate funding to support multi-centre collaboration, and validated biomarkers to stratify patients for platinum-based regimens, immunotherapy, or anti-angiogenic agents.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractUNLABELLED: Primary fallopian tube cancer constitutes 1% of gynecologic malignancies. Early clinical manifestation and prompt investigations lead to diagnosis in the early stage of disease accounting for a better survival compared with ovarian cancer. Principles of management generally follow that of epithelial ovarian cancer. This article reviews the current understanding of this rare cancer. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING OBJECTIVES: After completion of this article, the reader should be able to describe the clinical features of a patient with fallopian tube carcinoma, to list the prognostic factors associated with fallopian tube cancer, and to outline the treatment options for a patient with fallopian tube cancer.
Results of chemotherapy in advanced carcinoma of the fallopian tube
AbstractForty-six patients with measurable disease received chemotherapy for advanced primary or recurrent carcinoma of the fallopian tube. The response rate was 9% with single-agent therapy, 29% with multiagent therapy without cisplatin, and 81% with cisplatin-containing combination therapy. Survival was significantly improved in Stage III/IV with the addition of cisplatin-based combination therapy.
Asia-Pacific Journal of Clinical Oncology · 2012 · 24 citations
Carcinosarcoma of the fallopian tube: Report of four cases and review of literature
AbstractAIM: Carcinosarcoma of the fallopian tube is extremely rare and the therapeutic prognosis of this disease is unknown. METHODS: We report on four new cases of this disease and have reviewed 59 carcinosarcomas of the fallopian tube and analyzed the prognosis with respect to the chosen therapeutic method in order to explore the most appropriate therapy. RESULTS: Out of the 59 patients reviewed, the prognosis was examined in 51 patients that allowed it to be tracked. The 3-year survival rates were 63% for the 27 stage I/II patients and 40% for the 24 stage III/IV patients. The 3-year survival rates were 36% for the 14 surgery-alone patients, 59% for the 13 radiation therapy following surgery patients, 54% for the 27 chemotherapy following surgery patients (the chemotherapy group) and 100% in for the four chemoradiotherapy following surgery patients. A significant difference was observed between the surgery-alone and the chemotherapy groups (Wilcoxon test, P < 0.05), the chemoradiotherapy group demonstrating a better tendency as to survival rate than the surgery-alone group (Wilcoxon test, P = 0.06). Stage III/IV patients accounted for a two-thirds of the chemotherapy group. The 3-year survival rate for all the stage I-IV patients was 63% when a platinum drug was used and 21% when it was not used, suggesting the possibility of extending life through the use of a platinum drug. CONCLUSION: Chemotherapy using a platinum drug after surgery seems to be most effective treatment in this disease.
Geburtshilfe und Frauenheilkunde · 1981 · 15 citations
Das primäre Tubenkarzinom - Eine klinische Studie an 37 Patientinnen
AbstractThirty-seven cases of primary fallopian tube carcinoma treated at our institution over the years 1946 to 1976 are described. The overall 5-years survival rate was 30%, although patients with early tumors had 42% survival rate. The single most important factor affecting survival appeared to be the extent of disease at the time of diagnosis. Present treatment modalities are discussed, even though the number of tube carcinomas are few, it might be useful to adopt an official classification.
Journal of Nippon Medical School · 2021 · 3 citations · open access
Treatment of Carcinosarcoma of the Fallopian Tube Mimicking Ovarian Cancer: A Case Report and Genetic Analysis
AbstractCarcinosarcoma of the fallopian tube is an exceptionally rare gynecological neoplasm. It tends to have high metastatic potential, to frequently recur, and has a poor prognosis. For these reasons, treatment is difficult and there is no standardized therapy schedule for this disease. Here, we report a case of carcinosarcoma of the fallopian tube mimicking ovarian cancer, initially presenting as a rupture of a growth and subsequent hemoperitoneum. The 55-year-old woman underwent cytoreductive surgery and postoperative conventional platinum-based combination therapy. The anti-angiogenic drug bevacizumab was added, and no evidence of disease was found on follow-up images or tumor markers 51 months after surgical resection. We describe a rare case of carcinosarcoma of the fallopian tube, include an in-depth histopathological review with genetic analysis, and propose treatment with a platinum-based combination therapy including bevacizumab.
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel
AbstractRATIONALE: Primary fallopian tube carcinoma (PFTC) is an extremely rare but invasive malignancy with a dismal prognosis. Very few data exist on the salvage treatment for patients with PFTC. Here we report a case showing an impressive response to immunotherapy combined with chemotherapy, which have never been reported before on patients with metastatic PFTC. PATIENT CONCERNS: A 42-year-old woman, who was diagnosed with PFTC in 2010, had been failed of multiple systemic therapies and antiangiogenic therapy because of the disease recurrence and progression. DIAGNOSIS: Metastatic primary fallopian tube carcinoma. INTERVENTIONS: The patient underwent surgery in May 2010 and had multi-line chemotherapies plus an anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody for about 9 years. Due to treatment failure the patient accepted the immunotherapy with the checkpoint inhibitor, pembrolizumab, combined with nab-paclitaxel from December 2018 to April 2019. OUTCOMES: The patient showed a complete response after 6 cycles treatment. Thus far, the patient is taking pembrolizumab as maintenance and remains in good health. LESSONS: Pembrolizumab combined with chemotherapy for treatment of PFTC may provide a positive antitumor effect in multiple metastatic lesions, but more clinical evidence is needed to confirm the efficacy and safety.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
